Palani Santhosh 4

What Happened Palani Santhosh, a director of Acrivon Therapeutics, was granted 9,366 restricted stock units (RSUs) on May 18, 2026. The award is reported as an acquisition (Code A) at $0.00 per unit (total reported value $0). Each RSU represents a contingent right to receive one share of Acrivon common stock; the RSUs vest in full on May 18, 2027, subject to the reporting person’s continuous service through that date. This transaction is an equity award (compensation), not a market purchase or sale.

Key Details

• Transaction date: 2026-05-18; Filing date: 2026-05-20 (filed timely).
• Transaction type/code: Grant / Award (Code A).
• Quantity: 9,366 RSUs; Price per unit reported: $0.00; Reported value: $0.
• Vesting: RSUs vest in full on May 18, 2027, contingent on continuous service (footnote F1).
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Timely (filed within two business days of the transaction).

Context RSUs are deferred equity awards that convert to shares only upon vesting; no shares were issued immediately and no cash changed hands at grant. Director RSU grants are a common form of compensation and do not by themselves indicate insider buying or selling intent. For trading signals, outright purchases are typically more informative than compensation grants.